Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals

Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine but it has been much less straightforward than biopharmaceutical companies had expected Two contenders in this area Alnylam